Seleccionar página
We are now in numerous top level clinics in various countries

We are now in numerous top level clinics in various countries

Since the launch of BGaze child ADHD test at the EPA 2016 conference in Madrid we have installed the BGaze system in pioneer clinics in Spain, The Netherlands, UK, Germany and even the USA. In most of these sites, highly regarded psychiatrists use the BGaze test to enable a more objective and convincing diagnosis of ADHD in children and (very recently also) in adults.

BGaze is used both in public and private clinics to improve the diagnosis of ADHD in European countries as the BGaze ADHD test complies with the CE Mark Medical Device regulations across the EU. Overall more than 1000 diagnoses have been performed. Medical professionals are especially satisfied with BGaze being contributing to discriminate between ‘clear’ ADHD cases and those patients mainly suffering from other cognitive disorders such as anxiety, bipolar or dyslexia in a clinical population where high levels of ADHD prevalence occur.

Outside the EU, in countries where BGaze is not yet homologated for clinical use, psychiatrists can use BGaze for their scientific research into ADHD or other cognitive attention interests. Braingaze offers scientists specific services to facilitate their cognitive or clinical research, ranging from visual task development to data analysis. In some cases such research in turn leads to validated novel diagnostics or even treatment solutions, which can then be in-licensed by Braingaze to enable their introduction into the regular healthcare system.

First validation study results confirm usefulness in adult ADHD diagnostics

First validation study results confirm usefulness in adult ADHD diagnostics

In addition, we completed a first multi-site confirmation of the clinical usefulness of our BGaze ADHD test in adults, using clinical data on hundreds of subjects from various prestigious clinics across the world. You can read more here and download relevant posters presented at the Sixth World Congress on ADHD and 25th European Congress of Psychiatry.

We have adopted our BGaze test and validated it for supporting ADHD diagnosis in adults. We made the task slightly more difficult with more possible target locations and shorter presentation times. As in children, the adult BGaze test is a supportive tool for ADHD diagnosis. In the two main conditions of the task, BGaze cognitive vergence biomarker was present in control subjects but not in ADHD patients (see figure 3) .

.

Figure 3. Cognitive Vergence response of adults in the BGaze task.

Based on the biomarker assessment, BGaze can predict ADHD in adult patient with 90% accuracy. We have included the adult CPT version in our BGaze system, and it is now available.